Skip to content

Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol

Acceptability and Feasibility of Medical Abortion in Mexico, Puerto Rico, Armenia and Azerbaijan: A Study of Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days' Gestation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00386282
Enrollment
1250
Registered
2006-10-11
Start date
2006-09-30
Completion date
2011-03-31
Last updated
2014-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion, First Trimester

Keywords

Mifepristone, Misoprostol, Buccal administration

Brief summary

This study examined the acceptability and feasibility of introducing a mifepristone-misoprostol regimen of medical abortion into abortion services in two private clinics in Puerto Rico; 2 clinics in Baku, Azerbaijan; 3 clinics in Yerevan, Armenia; and 4 clinics in Mexico City. It was hypothesized that the study regimen would be both acceptable and efficacious.

Detailed description

The study recruited women with pregnancies up to 63 days gestation. Eligible women took 200 mg mifepristone, followed by 800 buccal misoprostol. They later underwent clinic follow-up to determine if their medical abortions were complete. The study assessed the acceptability and feasibility of the above regimen and sought to determine the efficacy and acceptability of buccal administration of misoprostol as well as the acceptability of side effects experienced by women.

Interventions

DRUGmifepristone-misoprostol treatment

200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.

Sponsors

Gynuity Health Projects
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Gestation up to 63 days * General good health * Willingness to provide contact information for follow-up * Absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination

Exclusion criteria

* Ectopic pregnancy * Intrauterine device (IUD) in place

Design outcomes

Primary

MeasureTime frame
efficacy15 days

Secondary

MeasureTime frame
acceptability15 days

Countries

Armenia, Azerbaijan, Mexico, Puerto Rico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026